What do HTA decisionmakers care about?

Is it clinical benefit? Cost? Value? The availability of treatment alternatives? To answer this question, a paper by Wranik et al. (2019) conducted a discrete choice experiment DCE to determine HTA stakeholders stated preferences. The sample consisted of HTA stakeholders from 5 countries: Australia, Canada, Germany, Poland, and the United Kingdom. The stakeholders included not only HTA committee members but also clinical and economic experts and, patients.

The attributes evaluated included survival benefit, adverse events, incremental health system cost per patient, number of patients eligible for treatment, and the availability of other treatment options. The authors first used DCE and